| Ytd | -37.80% | |
| 1y | -32.91% |
| Open | 30.83 | Prev Close | 30.61 | Low | 30.15 | High | 30.96 | Mkt Cap | 1.14B |
| Vol | 566.38K | Avg Vol | 564.04K | EPS | -0.99 | P/E | N/A | Forward P/E | 10.76 |
| Beta | 0.19 | Short Ratio | 15.23 | Inst. Own | 58.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 37.12 | 200-d Avg | 40.35 | 1yr Est | 65.00 |
Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) have earned a consensus rating of "Moderate
NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of op
Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) dropped 6.8% during trading on Monday. The c
Harrow (NASDAQ: HROW - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for th
Leerink Partners analyst Daniel Clark initiates coverage on Harrow (NASDAQ:HROW) with a Outperfor
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Harrow (NASDAQ: HROW) posts positive study results for IHEEZO ophthalmic gel, significantly reducing
Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America
U.S. stock futures mostly lower. OppFi (OPFI) shares fall after missing Q2 earnings and cutting FY26
Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000
Harrow (NASDAQ:HROW) reported quarterly losses of $(0.46) per share which missed the analyst consens
Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter ea
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (B
Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America
Harrow relaunches Verkazia for VKC treatment, targeting pediatric eye disease with a steroid-sparing
VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, pat
Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lo
U.S. stock futures lower, Nasdaq down 200 points. AST SpaceMobile shares dip 11% after reporting wor
Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising gui
Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000
Harrow (NASDAQ:HROW) reported quarterly losses of $(0.74) per share which missed the analyst consens
LogiCare3PL today announced it has been selected by Harrow, Inc. (NASDAQ:HROW) as a distribution par
B. Riley Securities analyst Mayank Mamtani reiterates Harrow (NASDAQ:HROW) with a Buy and lowers
The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and futu
Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lo
HC Wainwright & Co. analyst Yi Chen maintains Harrow (NASDAQ:HROW) with a Buy and raises the
Harrow stock drops after earnings miss and weak 2026 outlook, despite revenue growth and new product
MDB stock fell 27.2% in pre-market trading after reporting Q4 earnings of $1.65 per share, revenue o
The planned Phase 3 study is a randomized, placebo-controlled, double-masked, multicenter clinical t
Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported bet
Harrow (NASDAQ:HROW) reported quarterly earnings of $0.17 per share which missed the analyst consens
U.S. stock futures lower, Dow futures down 1%. Yatsen Holding shares fall 10.1%, while other stocks
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office
Ladenburg Thalmann analyst Jeffrey Cohen maintains Harrow (NASDAQ:HROW) with a Buy and raises the
HC Wainwright & Co. analyst Yi Chen maintains Harrow (NASDAQ:HROW) with a Buy and raises the